Laquinimod: Few cheers for BRAVO results


Early results from the phase III trial of laquinimod indicate that the drug is no more effective than placebo in reducing relapses, according to a press release issued by Teva Pharmaceuticals ( and an August 1st webcast to investors ( More complete results from the trial are expected to be presented later this year at the European Committee for Treatment and Research in MS (ECTRIMS) annual conference in Amsterdam.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page